experiment
studi
conduct
evalu
two
speci
cotton
rat
sigmodon
hispidu
sigmodon
fulvivent
model
sever
acut
respiratori
syndrom
sar
blood
turbin
wash
sampl
lung
tissu
collect
anim
differ
time
point
sar
coronaviru
cov
infect
determin
growth
curv
viru
standard
infect
assay
vero
cell
addit
section
lung
liver
spleen
kidney
taken
use
histolog
analysi
anim
observ
daili
sign
ill
experi
anim
weigh
day
sacrif
result
indic
cotton
rat
speci
hispidu
fulvivent
use
model
either
sarscov
infect
diseas
observ
support
absenc
sign
ill
failur
consist
demonstr
viru
blood
tissu
absent
notabl
histopatholog
howev
infect
anim
capabl
produc
neural
antibodi
sarscov
suggest
seroconvers
occur
studi
warrant
consid
anim
speci
effort
find
better
anim
model
evalu
sarscov
vaccin
antivir
drug
key
word
cotton
ratssarsmodel
anim
inc
outbreak
sever
acut
respiratori
syndrom
sar
global
research
effort
underway
establish
suitabl
anim
speci
model
human
diseas
peiri
et
al
sever
laboratori
anim
speci
shown
support
replic
caus
agent
sar
coronaviru
sarscov
diseas
similar
report
human
seen
robert
et
al
tseng
et
al
mccray
et
al
although
model
proven
use
studi
pathogenesi
evalu
antivir
drug
vaccin
idea
model
would
singl
suitabl
anim
speci
tseng
et
al
therefor
object
present
studi
evalu
two
speci
cotton
rat
sigmodon
hispidu
sigmodon
fulvivent
aim
find
better
model
sarscov
infect
humanlik
sar
diseas
cotton
rat
hispidu
document
suitabl
model
respiratori
viral
diseas
obtain
commerci
sourc
reagent
avail
studi
immun
respons
niewiesk
princ
ottolini
et
al
blanco
et
al
experiment
approach
studi
evalu
cotton
rat
potenti
model
sarscov
infect
diseas
first
determin
either
speci
suscept
infect
suscept
second
detail
experi
perform
determin
clinic
sign
biodistribut
viru
patholog
associ
infect
male
femal
inbr
sigmodon
hispidu
use
first
second
experi
obtain
breed
coloni
unknown
gener
univers
texa
medic
branch
utmb
galveston
texa
virion
system
rockvil
maryland
respect
sigmodon
fulvivent
includ
male
femal
obtain
breed
coloni
unknown
gener
maintain
virion
system
inc
cotton
rat
purchas
virion
system
certifi
seroneg
adventiti
virus
anim
hous
larg
polycarbon
cage
fed
diet
standard
rodent
chow
water
use
week
age
cotton
rat
agerang
weigh
approxim
g
match
age
weight
use
differ
group
anim
anesthet
isofluran
manipul
sacrif
isofluran
asphyxi
collect
tissu
sampl
anim
experi
approv
utmb
institut
anim
care
use
committe
urbani
strain
sarscov
vero
passag
level
kindli
provid
tg
ksiazek
center
diseas
control
prevent
use
throughout
studi
vero
cell
american
type
cultur
collect
use
prepar
sarscov
viru
stock
viral
infect
assay
base
observ
viral
specif
cytopath
effect
describ
previous
tseng
et
al
stock
prepar
passag
viru
twice
vero
cell
multipl
infect
passag
titer
express
tissu
cultur
infecti
dose
tcid
ml
stock
viru
aliquot
store
use
experi
addit
use
stock
viru
inoculum
infect
anim
neutral
test
separ
aliquot
titrat
time
blood
tissu
sampl
test
serv
control
verifi
infect
assay
perform
properli
experi
involv
infecti
viru
conduct
biosafeti
level
laboratori
utmb
cotton
rat
inocul
isofluran
anesthesia
via
intranas
rout
l
contain
tcid
sarscov
two
control
anim
experi
inocul
via
rout
l
steril
phosphatebuff
salin
pb
supplement
fetal
calf
serum
fc
antibiot
dose
viru
experi
confirm
titrat
vero
cell
express
tcid
per
ml
describ
previous
tseng
et
al
four
experi
conduct
two
involv
two
sourc
hispidu
two
involv
fulvivent
three
experi
anim
predesign
sacrific
day
postinocul
pi
obtain
select
tissu
sampl
day
pi
four
anim
sacrif
includ
one
neg
control
three
virusinocul
anim
day
pi
three
virusinocul
anim
sacrif
blood
sampl
obtain
day
remain
anim
antibodi
test
base
dilut
serum
neutral
constant
dose
sarscov
produc
cytopath
effect
vero
cell
cultur
first
fulvivent
experi
anim
observ
sign
ill
weigh
day
blood
sampl
taken
day
antibodi
test
blood
turbin
wash
sampl
tissu
includ
lung
heart
liver
spleen
kidney
collect
anim
viral
infect
assay
vero
cell
tseng
et
al
blood
turbin
sampl
dilut
steril
pb
supplement
fc
streptomycin
penicillin
mgml
tissu
sampl
transfer
steril
vial
sampl
store
immedi
homogen
test
viru
assay
sampl
rapid
thaw
weigh
homogen
steril
pb
supplement
fc
use
tissuelys
yield
tissuepb
suspens
suspens
clarifi
centrifug
test
vero
cell
viru
titer
individu
sampl
express
tcid
per
ml
suspens
addit
sampl
lung
heart
liver
spleen
kidney
taken
place
neutral
buffer
formalin
h
transfer
ethanol
histolog
analysi
describ
anim
observ
daili
sign
ill
experi
anim
weigh
daili
remain
anim
euthan
overdos
isofluran
via
inhal
rout
end
experi
tissu
includ
lung
heart
liver
spleen
kidney
obtain
sarscov
inocul
control
anim
process
histolog
immunohistochemistri
ihc
accord
publish
techniqu
tseng
et
al
subbarao
et
al
tissu
section
fix
buffer
formalin
h
transfer
ethanol
later
paraffin
embed
histopatholog
evalu
perform
deparaffin
section
stain
routin
hematoxylinandeosin
stain
ihc
test
sarscov
use
previous
describ
colorimetr
indirect
immunoalkalin
phosphatas
method
tseng
et
al
rabbit
antisarscov
nucleocapsid
protein
antibodi
imgenex
catalog
normal
mous
goat
sera
use
neg
control
sarscov
antigen
posit
vero
cell
use
posit
control
primari
antibodi
detect
either
biotinyl
swine
antirabbit
immunoglobulin
dako
catalog
rabbit
antigoat
immunoglobulin
kpl
catalog
secondari
antibodi
visual
achiev
incub
streptavidinalkalin
phosphatas
naphtholfast
red
substrat
dako
counterstain
mayer
hematoxylin
sigmaaldrich
co
st
loui
mo
sigmodon
hispidu
utmb
coloni
deriv
florida
rat
pilot
experi
assess
suscept
speci
sarscov
infect
total
anim
inocul
via
intranas
rout
l
contain
tissu
cultur
dose
tcid
sarscov
two
control
anim
inocul
salin
supplement
fc
antibiot
tabl
six
anim
includ
two
control
die
unknown
caus
experi
possibl
die
sarscov
exclud
failur
detect
viru
necropsi
tissu
use
vero
cell
assay
addit
similar
pattern
mortal
observ
utmb
cotton
rat
coloni
anim
surviv
day
pi
none
show
sign
ill
blood
sampl
taken
day
neg
sarscov
antibodi
experi
perform
cotton
rat
utmb
coloni
question
health
statu
coloni
commerci
procur
hispidu
inocul
tcid
sarscov
none
show
overt
sign
ill
lost
weight
tabl
viru
recov
nasal
wash
sampl
obtain
three
anim
day
three
four
anim
day
pi
titer
day
anim
day
rang
none
nasal
wash
sampl
posit
day
pi
viru
also
detect
lung
one
three
anim
day
pi
titer
lung
sampl
taken
four
anim
day
neg
viru
viru
detect
blood
sampl
evid
viru
vero
cell
assay
ihc
stain
tissu
deriv
lung
heart
liver
spleen
kidney
specimen
control
anim
includ
lung
show
patholog
evid
viral
specif
stain
tissu
although
viru
recov
nasal
wash
sampl
lung
one
anim
like
low
titer
repres
residu
viru
inoculum
failur
demonstr
detect
viru
tissu
addit
anim
becom
infect
support
absenc
sarscov
neutral
blood
sampl
taken
five
anim
day
pi
find
indic
hispidu
suitabl
model
sar
pilot
experi
assess
suscept
sigmodon
fulvivent
sarscov
infect
anim
inocul
tcid
sarscov
two
control
anim
inocul
pb
fc
antibiot
tabl
none
anim
develop
sign
ill
observ
period
howev
day
pi
blood
sampl
anim
test
detect
antibodi
rang
titer
two
control
neg
antibodi
thu
posit
serolog
data
indic
fulvivent
suscept
sarscov
infect
therefor
second
experi
perform
evalu
fulvivent
total
fulvivent
inocul
tcid
sarscov
two
control
anim
inocul
salin
supplement
fc
antibiot
tabl
sign
ill
observ
anim
none
lost
weight
experi
attempt
detect
viru
nasal
wash
blood
sampl
taken
anim
use
vero
tissu
cultur
unsuccess
although
lung
histolog
reveal
mild
interstiti
pneumonia
four
six
anim
sacrif
day
pi
lung
tissu
sampl
well
tissu
sampl
deriv
heart
liver
spleen
kidney
anim
neg
viru
ihc
stain
assay
vero
cell
reason
mild
patholog
infect
anim
unknown
sinc
specimen
control
anim
includ
lung
show
either
patholog
viral
antigen
tissu
howev
blood
five
anim
taken
day
pi
posit
neutral
antibodi
titer
rang
sampl
control
anim
antibodi
neg
find
confirm
previou
observ
fulvivent
appear
suscept
infect
sarscov
infect
must
mild
transient
effort
identifi
anim
speci
model
human
sar
diseas
employ
mani
common
laboratori
anim
rang
mice
nonhuman
primat
robert
et
al
anim
eg
hamster
age
mice
transgen
mice
bear
sarscov
receptor
mice
infect
serial
passag
adapt
viru
recent
yield
promis
result
diseas
model
robert
et
al
tseng
et
al
mccray
et
al
first
experi
neutral
antibodi
detect
hispidu
day
postexposur
tcid
sarscov
sinc
health
statu
anim
suspect
evid
infect
experi
perform
anim
deriv
utmb
coloni
therefor
second
experi
perform
commerci
purchas
hispidu
likewis
neutral
antibodi
detect
day
postexposur
tcid
sarscov
thu
indic
speci
suscept
infect
use
dose
viru
contrast
two
subsequ
experi
fulvivent
becam
infect
follow
exposur
dose
viru
indic
detect
antibodi
anim
day
postexposur
viru
even
though
infect
demonstr
none
anim
show
sign
ill
conclus
evid
viral
replic
select
tissu
reason
differ
suscept
two
speci
sarscov
unknown
sex
age
two
speci
gener
anim
could
differ
possibl
influenc
suscept
unknown
failur
infect
fulvivent
lose
weight
possibl
evid
clinic
ill
follow
exposur
tcid
sarscov
contradict
report
observ
lethal
infect
transgen
mice
lost
much
bodi
weight
follow
infect
similar
dose
viru
strain
tseng
et
al
addit
recent
studi
character
strain
transgen
mice
develop
fatal
infect
weight
loss
consist
indic
sarscov
infect
tseng
et
al
other
report
weight
loss
clinic
outcom
sarscov
infect
inbr
mice
robert
et
al
although
weight
loss
reliabl
indic
sarscov
infect
mice
result
may
applic
cotton
rat
exampl
cotton
rat
excel
model
respiratori
virus
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
infect
virus
result
loss
weight
thu
weight
loss
must
interpret
caution
possibl
respons
variat
among
mammalian
speci
although
fulvivent
becam
infect
evid
sarscov
replic
detect
select
tissu
obtain
first
week
follow
exposur
viru
detect
viru
earli
exposur
believ
reflect
residu
viral
inoculum
sporad
pattern
low
titer
viru
howev
lowlevel
viral
replic
exclud
detect
level
cell
cultur
assay
nevertheless
lack
clinic
sign
ill
absenc
confirm
viral
induc
patholog
tissu
fulvivent
consid
warrant
evalu
potenti
model
sarscov
infect
overal
effort
involv
hispidu
fulvivent
yield
use
model
either
infect
diseas
observ
support
absenc
sign
ill
failur
demonstr
viru
tissu
consist
absenc
confirm
viru
induc
histopatholog
addit
sarscov
antibodi
detect
hispidu
evid
speci
suscept
infect
howev
recent
data
indic
strain
sarscov
serial
passag
viru
use
age
anim
offer
altern
approach
provid
better
anim
model
evalu
sarscov
vaccin
antivir
drug
robert
et
al
